OPKO Health, Inc. Investment Income, Interest
OPKO Health, Inc. (OPK) reported Investment Income, Interest of $3.22 million for the 3-month period ending 2026-06-30, per its 10-Q/A filed 2026-08-28.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-28
- OPKO Health, Inc. investment income, interest for the quarter ending 2026-06-30 was $3.22M, a 2.01% decline year-over-year.
- OPKO Health, Inc. investment income, interest for the quarter ending 2026-03-31 was $3.01M, a 35.76% decline year-over-year.
- OPKO Health, Inc. investment income, interest for the quarter ending 2025-12-31 was $3.82M, a 11.04% decline year-over-year.
- OPKO Health, Inc. investment income, interest for the quarter ending 2025-09-30 was $3.02M, a 3.24% increase year-over-year.
- OPKO Health, Inc. investment income, interest for fiscal 2025 was $14.81M, a 75.78% increase from fiscal 2024.
- OPKO Health, Inc. investment income, interest for fiscal 2024 was $8.43M, a 111.55% increase from fiscal 2023.
- OPKO Health, Inc. investment income, interest for fiscal 2023 was $3.98M, a 101.06% increase from fiscal 2022.
- OPKO Health, Inc. investment income, interest for fiscal 2022 was $1.98M, a 6975.00% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.22M 10-Q/A · filed 2026-08-28 | $6.23M 10-Q/A · filed 2026-08-28 | $10.05M derived: sum of 3 quarters · filed 2026-08-28 | $13.07M derived: sum of 4 quarters · filed 2026-08-28 |
| 2026-03-31 | $3.01M 10-Q/A · filed 2026-08-28 | $6.83M derived: sum of 2 quarters · filed 2026-08-28 | $9.85M derived: sum of 3 quarters · filed 2026-08-28 | $13.14M derived: sum of 4 quarters · filed 2026-08-28 |
| 2025-12-31 | $3.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.84M derived: sum of 2 quarters · filed 2026-02-26 | $10.13M derived: sum of 3 quarters · filed 2026-08-28 | $14.81M 10-K · filed 2026-02-26 |
| 2025-09-30 | $3.02M 10-Q · filed 2025-10-29 | $6.31M derived: sum of 2 quarters · filed 2026-08-28 | $10.99M 10-Q · filed 2025-10-29 | $15.29M derived: sum of 4 quarters · filed 2026-08-28 |
| 2025-06-30 | $3.29M 10-Q/A · filed 2026-08-28 | $7.97M 10-Q/A · filed 2026-08-28 | $12.26M derived: sum of 3 quarters · filed 2026-08-28 | $15.19M derived: sum of 4 quarters · filed 2026-08-28 |
| 2025-03-31 | $4.68M 10-Q/A · filed 2026-08-28 | $8.97M derived: sum of 2 quarters · filed 2026-08-28 | $11.90M derived: sum of 3 quarters · filed 2026-08-28 | $12.29M derived: sum of 4 quarters · filed 2026-08-28 |
| 2024-12-31 | $4.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $7.22M derived: sum of 2 quarters · filed 2026-02-26 | $7.61M derived: sum of 3 quarters · filed 2026-02-26 | $8.43M 10-K · filed 2026-02-26 |
| 2024-09-30 | $2.93M 10-Q · filed 2025-10-29 | $3.32M derived: sum of 2 quarters · filed 2025-10-29 | $4.13M 10-Q · filed 2025-10-29 | $5.04M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $391.00K 10-Q · filed 2025-07-31 | $1.20M 10-Q · filed 2025-07-31 | $2.11M derived: sum of 3 quarters · filed 2026-02-26 | $3.08M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $813.00K 10-Q · filed 2025-05-01 | $1.72M derived: sum of 2 quarters · filed 2026-02-26 | $2.69M derived: sum of 3 quarters · filed 2026-02-26 | $3.77M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $906.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.88M derived: sum of 2 quarters · filed 2026-02-26 | $2.95M derived: sum of 3 quarters · filed 2026-02-26 | $3.98M 10-K · filed 2026-02-26 |
| 2023-09-30 | $970.00K 10-Q · filed 2024-11-07 | $2.05M derived: sum of 2 quarters · filed 2024-11-07 | $3.08M 10-Q · filed 2024-11-07 | $4.22M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $1.08M 10-Q · filed 2024-08-07 | $2.11M 10-Q · filed 2024-08-07 | $3.25M derived: sum of 3 quarters · filed 2025-03-03 | $3.92M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $1.03M 10-Q · filed 2024-05-07 | $2.17M derived: sum of 2 quarters · filed 2025-03-03 | $2.84M derived: sum of 3 quarters · filed 2025-03-03 | $3.00M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $1.81M derived: sum of 2 quarters · filed 2025-03-03 | $1.97M derived: sum of 3 quarters · filed 2025-03-03 | $1.98M 10-K · filed 2025-03-03 |
| 2022-09-30 | $667.00K 10-Q · filed 2023-11-06 | $828.00K derived: sum of 2 quarters · filed 2023-11-06 | $838.00K 10-Q · filed 2023-11-06 | |
| 2022-06-30 | $161.00K 10-Q · filed 2023-08-03 | $171.00K 10-Q · filed 2023-08-03 | ||
| 2021-12-31 | $28.00K 10-K · filed 2024-03-01 | |||
| 2012-03-31 | $27.00K 10-Q · filed 2012-05-10 | |||
| 2011-12-31 | $288.00K 10-K · filed 2012-03-15 | |||
| 2011-03-31 | $8.00K 10-Q · filed 2012-05-10 | |||
| 2010-12-31 | $24.00K 10-K · filed 2012-03-15 | |||
| 2009-12-31 | $24.00K 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |